Approach to invasive pulmonary aspergillosis in critically ill patients
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Apparently immunocompetent critically ill patients represent an increasing population at risk for invasive pulmonary aspergillosis (IPA). The current review gives an update on the epidemiology, diagnosis, and management of IPA in the ICU. RECENT FINDINGS: Patients without apparent severe immunosuppression (e.g. chronic obstructive pulmonary disease, decompensated liver disease, etc.) represent the majority of ICU IPA cases. IPA diagnosis is problematic and the true incidence of IPA is difficult to be estimated because of the nonspecific clinical presentation. A user-friendly clinical diagnostic algorithm for IPA is valuable, particularly through a high negative predictive value. IPA carries a poor prognosis and has an important impact on hospital costs. Timely diagnosis and prompt administration of appropriate treatment may improve the outcomes. Intravenous voriconazole is the recommended primary IPA treatment, but liposomal amphotericin B also has clinical utility. Voriconazole presents bioavailability and toxicity issues, and drug level monitoring is advocated. Caspofungin or antifungal combinations are recommended as salvage therapy. SUMMARY: A high level of suspicion in critically ill patients presenting with Aspergillus-positive respiratory tract cultures or nonresolving pulmonary infection may lead to earlier IPA diagnosis. Dosage individualization may decrease treatment discontinuation and improve clinical efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917 · cited 3×
“The strict EORTC/MSG criteria (Table 2) [12] fail to diagnose IPA in patients without the ‘classic’ host factors’ [2 && ,11,12,32,33].”
BackgroundMethodVoriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Ostrosky-Zeichner, L., Alexander, B. D., Kett, D. H., Vazquez, J., Pappas, P. G., Saeki, F., Ketchum, P. A., Wingard, J., Schiff, R., Tamura, H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432470 · Cited by 669 · cited 1×
“Its detection provides diagnostic information for IPA in oncohematological patients with neutropenia [43,44].”
BackgroundInvasive aspergillosis in critically ill patients without malignancy
Meersseman, W., Vandecasteele, S. J., Wilmer, A., Verbeken, E., Peetermans, W. E., & Van Wijngaerden, E. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200401-093oc · Cited by 547
Invasive aspergillosis in the intensive care unit
Meersseman, W., Lagrou, K., Maertens, J., & Wijngaerden, E. V. (2007) · Clinical Infectious Diseases · doi:10.1086/518852 · Cited by 366
Xu, H., Li, L., Huang, W.-J., Wang, L.-X., Li, W.-F., & Yuan, W.-F. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03503.x · Cited by 95
Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis
Cornely, O. A., Vehreschild, J. J., Vehreschild, M. J. G. T., Würthwein, G., Arenz, D., Schwartz, S., Heussel, C. P., Silling, G., Mahne, M., Franklin, J., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05134-11 · Cited by 93
Kim, A., Nicolau, D. P., & Kuti, J. L. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01903.x · Cited by 60
Cited by
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Self-citationSchauwvlieghe, A. F. A. D., Rijnders, B. J. A., Philips, N., Verwijs, R., Vanderbeke, L., Van Tienen, C., Lagrou, K., Verweij, P. E., Van de Veerdonk, F. L., Gommers, D., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30274-1 · Cited by 886
Taccone, F. S., Van den Abeele, A.-M., Bulpa, P., Misset, B., Meersseman, W., Cardoso, T., Paiva, J.-A., Blasco-Navalpotro, M., De Laere, E., Dimopoulos, G., et al. (2015) · Critical Care · doi:10.1186/s13054-014-0722-7 · Cited by 405
Self-citationPharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Diagnosis of aspergillosis by PCR: Clinical considerations and technical tips
Barnes, R. A., White, P. L., Morton, C. O., Rogers, T. R., Cruciani, M., Loeffler, J., & Donnelly, J. P. (2018) · Medical Mycology · doi:10.1093/mmy/myx091 · Cited by 68
Metadata
- Authors
- Koulenti, D., Garnacho-Montero, J., & Blot, S.
- Venue
- Current Opinion in Infectious Diseases
- Published
- 2014-04
- Volume
- 27
- Issue
- 2
- Pages
- 174-183
- ISSN
- 0951-7375 (ISSN-L)
- OpenAlex
- W2017138972
- Cited by
- 81
- References
- 8
- FWCI
- 6.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Approach to invasive pulmonary aspergillosis in critically ill patients. https://app.cochat.ai/papers/10.1097/qco.0000000000000043
- The paper
- Koulenti, D., Garnacho-Montero, J., & Blot, S. (2014). Approach to invasive pulmonary aspergillosis in critically ill patients. Current Opinion in Infectious Diseases. https://doi.org/10.1097/qco.0000000000000043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.